Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Z Li

Showing results (241-250 of 270) with videos related to

Pageof 27
Sort By:
Nature Microbiology|October 27, 2022
Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trialManish C Choudhary, Kara W Chew, Rinki Deo, et al.
Plos Pathogens|May 12, 2026
Extensive diversity and impact of drug-resistant HIV-1 variants in individuals with prior virologic failureMelendhran Pillay, Manish C Choudhary, Rinki Deo, et al.
Immunity|April 29, 2021
Notch4 signaling limits regulatory T-cell-mediated tissue repair and promotes severe lung inflammation in viral infectionsHani Harb, Mehdi Benamar, Peggy S Lai, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 22, 2025
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: VilobelimabNandita Nadig, Adarsh Bhimraj, Kelly Cawcutt, et al.
The Journal of Pediatrics|September 21, 2020
ReplyLael M Yonker, Anne M Neilan, Yannic Bartsch, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 9, 2025
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: AbataceptNandita Nadig, Adarsh Bhimraj, Kelly Cawcutt, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 4, 2025
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical IllnessAdarsh Bhimraj, Yngve Falck-Ytter, Lindsey R Baden, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 20, 2025
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: InfliximabNandita Nadig, Adarsh Bhimraj, Kelly Cawcutt, et al.
Plos One|March 8, 2014
Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapyJonathan Z Li, Brad Chapman, Patrick Charlebois, et al.
The Journal of Pediatrics|September 24, 2020
ReplyLael M Yonker, Anne M Neilan, Yannic Bartsch, et al.
Pageof 27

Showing results (241-250 of 270) with videos related to

Sort By:
Pageof 27
Nature Microbiology|October 27, 2022
Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trialManish C Choudhary, Kara W Chew, Rinki Deo, et al.
Plos Pathogens|May 12, 2026
Extensive diversity and impact of drug-resistant HIV-1 variants in individuals with prior virologic failureMelendhran Pillay, Manish C Choudhary, Rinki Deo, et al.
Immunity|April 29, 2021
Notch4 signaling limits regulatory T-cell-mediated tissue repair and promotes severe lung inflammation in viral infectionsHani Harb, Mehdi Benamar, Peggy S Lai, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 22, 2025
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: VilobelimabNandita Nadig, Adarsh Bhimraj, Kelly Cawcutt, et al.
The Journal of Pediatrics|September 21, 2020
ReplyLael M Yonker, Anne M Neilan, Yannic Bartsch, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 9, 2025
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: AbataceptNandita Nadig, Adarsh Bhimraj, Kelly Cawcutt, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 4, 2025
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical IllnessAdarsh Bhimraj, Yngve Falck-Ytter, Lindsey R Baden, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 20, 2025
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: InfliximabNandita Nadig, Adarsh Bhimraj, Kelly Cawcutt, et al.
Plos One|March 8, 2014
Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapyJonathan Z Li, Brad Chapman, Patrick Charlebois, et al.
The Journal of Pediatrics|September 24, 2020
ReplyLael M Yonker, Anne M Neilan, Yannic Bartsch, et al.
Pageof 27